TY - JOUR
T1 - Richter transformation in the era of novel agents
AU - Ding, Wei
N1 - Publisher Copyright:
© 2018 American Society of Hematology. All rights reserved.
PY - 2018/11/30
Y1 - 2018/11/30
N2 - Recent approvals of several oral targeted agents have revolutionized chronic lymphocytic leukemia (CLL) therapy. However, CLL patients continue to progress; particularly, 4% to 20% of previously treated CLL patients undergo transformation into high-grade lymphoma. Richter transformation is defined as a transformation of CLL into aggressive lymphoma, most commonly diffuse large B-cell lymphoma. These patients typically have poor response to traditional chemotherapy used to treat de novo diffuse large B-cell lymphoma and similar or shorter overall survival (median 3-11 months) in the era of novel agents. Here, I review the contemporary literature on Richter transformation, particularly in the context of novel agents used in CLL, and discuss the management approach for these patients.
AB - Recent approvals of several oral targeted agents have revolutionized chronic lymphocytic leukemia (CLL) therapy. However, CLL patients continue to progress; particularly, 4% to 20% of previously treated CLL patients undergo transformation into high-grade lymphoma. Richter transformation is defined as a transformation of CLL into aggressive lymphoma, most commonly diffuse large B-cell lymphoma. These patients typically have poor response to traditional chemotherapy used to treat de novo diffuse large B-cell lymphoma and similar or shorter overall survival (median 3-11 months) in the era of novel agents. Here, I review the contemporary literature on Richter transformation, particularly in the context of novel agents used in CLL, and discuss the management approach for these patients.
UR - http://www.scopus.com/inward/record.url?scp=85058770743&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058770743&partnerID=8YFLogxK
U2 - 10.1182/asheducation-2018.1.256
DO - 10.1182/asheducation-2018.1.256
M3 - Article
C2 - 30504319
AN - SCOPUS:85058770743
SN - 1520-4391
VL - 2018
SP - 256
EP - 263
JO - Hematology (United States)
JF - Hematology (United States)
IS - 1
ER -